Novo Nordisk A/S (NVO) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$39.14 +2.22% NYSE • Public Delayed / 60s Snapshot

Novo Nordisk A/S (NVO) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.

ROARABLE C+ • HOLD / WATCH Cap $173.31B

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+3.6% Base Target

WHALE OPTIONS TUG-OF-WAR:60% Call Buyers ($18.7M)

40% PutsMax Pain: $38.00

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

NVO Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (NVO)

No recent open-market Form 4 cluster sales or emergency dumps flagged on NVO. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk

Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live NVO Tape Review)

✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen

RQD INSIDER CLUB UPGRADE$49/YEAR

Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?

🤖 Try AI Indicator Builder ($49/yr VIP) →$100K Arena

NVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -5.26%📐 HORIZONTAL RANGE

2026-10-30O $39.61H $40.10L $39.54C $40.00VOL 15.25M

RES: $58.40SUP: $34.06SMA50: $41.23SMA200: $44.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NVO Butterfly Map → + Track NVO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. +2.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NVO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

LLY → NVO Confirmed Filing

Eli Lilly dual GIP/GLP-1 agonist tirzepatide (Zepbound/Mounjaro) demonstrated superior head-to-head weight loss vs. Novo Nordisk semaglutide (Wegovy) in SURMOUNT-5, intensifying PBM rebate competition.

NVO → ISRG Confirmed Filing

Intuitive Surgical explicitly disclosed in its Form 10-K that US bariatric surgery procedure volumes on da Vinci robotic systems slowed as patients trialed GLP-1 weight-loss drugs prior to surgery.

DHR → NVO Analyst Hypothesis

Novo Nordisk $6B+ annual API manufacturing expansions utilize downstream purification chromatography resins and single-use filtration consumables where Danaher Cytiva and Pall hold leading bioprocess share.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

NVO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are NVO insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies NVO leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: NVO RQD Cockpit NVO 12M Forecast NVO Earnings & Move NVO Dividends & DRIP NVO Insiders & 13F NVO Whale Options NVO Profit Sankey NVO News & Why